VC-01: Phase I/II started

ViaCyte began an open-label, dose-escalation, North American Phase I/II trial to evaluate VC-01 in 40 Type I diabetics. The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ, New...